ClinicalTrials.gg
TerminatedNCT00934635Updated Feb 11, 2014Results posted

A Positron-Emission-Tomography (PET) Study to Measure the Blockade of Dopamine Receptors (D2) in Specific Areas of the Brain in Relation to the Plasma Concentrations of Paliperidone Extended Release (ER) and Oral Risperidone in Schizophrenia Patients and Healthy Controls

A Phase 4 interventional study of Paliperidone ER and Oral risperidone in Schizophrenia, sponsored by Janssen-Cilag G.m.b.H. Terminated at 1 site in Germany. Open to participants aged 18 Years to 50 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2014-02-11.

Sponsored by Janssen-Cilag G.m.b.H (part of Johnson & Johnson) · Phase 4, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
2
Allocation
Non-randomized
Ages
18 Years to 50 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 115 studies testing paliperidone in Schizophrenia — 6 open to participants now, 6 under way, none of them phase 3. paliperidone · Schizophrenia.

Enrollment
113th of 115
2 · median 178
Started
2009
with 10 others
Phase 4
42 of 115
5 open now
Registered
48th of 115
by date

Among the 115 studies testing paliperidone in Schizophrenia, this one is the 113th largest by enrollment, is one of 11 that started in 2009, is one of 42 in phase 4, and was the 48th registered.

Schizophrenia

3,571 studies on the registry are indexed under Schizophrenia; 493 are open to participants now.

Browse Schizophrenia studies →

Open to participants now

6 of the 115 studies testing paliperidone in Schizophrenia are open now, in 4 countries. Recruiting first, the newest first:

1 more — sign in →

By country, each count listing its studies:

All 6 open studies →

About paliperidone

paliperidone: first FDA approval 2006 (INVEGA), first EMA approval 2007. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 332 Schizophrenia studies recruiting now, 63 (19%) set no upper age limit and 258 (78%) stop at 75 or younger; 42 take children under 18; 83 take healthy volunteers.

This study: 18 Years to 50 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 115 studies testing paliperidone in Schizophrenia, or all of them as a file.
02

Study summary

The primary objective of this study is to compare the effect of two different antipsychotic compounds which are used in the treatment of schizophrenia (paliperidone ER and risperidone) at their target sites in two specific areas of the brain in patients with schizophrenia. A specialized X-ray known as Positron Emission Tomography (PET) Imaging is used to assess the areas of the brain targeted by both compounds.

Read the detailed description

This is an open-label (all people involved know the identity of the intervention), non-randomized (patients are assigned to treatment groups), phase IV, monocentric (at one single study site) interventional study evaluating the blocking effects two different doses of paliperidone ER and oral risperidone have on the dopamine D2 receptors in the brain of subchronic patients with schizophrenia. Dopamine is a substance produced and released in the brain. Research indicates that dopamine levels are elevated in some areas of the brain in acute schizophrenia psychosis. Antipsychotic medications like risperidone and paliperidone ER are used to treat psychosis by blocking the dopamine receptors. Fallypride is a radioactive tracer (a drug that emits radioactivity) that binds to the dopamine receptors in the brain much the same as antipsychotic medications. It competes with the antipsychotic compounds at the binding sites and is used when performing a specialized x-ray known as Positron Emission Tomography (PET) Imaging. After a patient receives Fallypride, it temporally binds to specific target areas in the brain and emits a brief and harmless radioactive signal that is detected by the PET Scanner. Since paliperidone ER and risperidone compete with Fallypride at the same target sites, the signal will differ according to the binding effect of the compound. This technique provides an image showing the direct effect medication has on the human brain and allows for comparisons of the effects of different medications to be made. As this effect will fluctuate depending on the concentration of the drug in the blood, during this study, PET measurements will be correlated with the blood levels sampled. Patients will receive either paliperidone ER (6 patients with 6 mg per day, 6 patients with 9 mg per day) or oral risperidone (6 patients with 4 mg per day, 6 patients with 6 mg per day). The primary objective of this study is to compare the blocking effects each medication has on the dopamine D2 receptors at different time points (shortly after taking medication and 24 hours after taking medication) correlated with blood levels of the medication. The study consists of 3 visits on 3 consecutive days. Blood levels will be assessed for treatment groups 1 to 4 on day 2 and day 3 and for groups 5 to 8 on day 3 (according to the last intake of study medication). PET-Scans will be assessed for every group on day 3. Group 1 to 4 consists of patients whose PET Scan will be assessed approximately 2 hours after taking medication (group 1 receives paliperidone ER 6 mg, group 2 receives paliperidone ER 9 mg, group 3 receives risperidone 4 mg, group 4 receives risperidone 6 mg). Group 5 to 8 consists of patients whose PET Scan will be assessed approximately 24 hours after taking medication (group 5 receives paliperidone ER 6 mg, group 6 receives paliperidone ER 9 mg, group 7 receives risperidone 4 mg, group 8 receives risperidone 6 mg). Adverse Events (AE's) will be assessed as reported spontaneously throughout the trial. The dose of antipsychotic medication will represent the most frequent dose used in post acute treatment of schizophrenia. A group of healthy volunteers (group 9) will serve as a control group to measure fallypride dopamine D2- receptor occupancies under normal circumstances, in patients not affected by schizophrenia. Patients will receive the same dosage throughout the study as prescribed prior to the start of the study either paliperidone ER 6 mg tablet once daily or 9 mg tablet once daily or risperidone 4 mg tablet once daily or 6 mg daily (two 3 mg tablets).

03

Conditions studied

  • Schizophrenia

Browse trials for

Keywords

  • D2-receptor occupancy
  • Antipsychotic drugs
  • Paliperidone ER, Oral risperidone
  • Dopamine
  • Fallypride
  • Plasma concentration
  • Therapeutic window, Healthy controls
04

Who can participate

Ages eligible
18 Years to 50 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients with a diagnosis of schizophrenia according to (DSM-IV) criteria
  • Patients with a specified severity of the disease (Clinical Global Impression Scale of Severity (CGI-S) range of > 2 \< 5)
  • Patients must be on antipsychotic medication with either paliperidone ER or oral risperidone in monotherapy for at least two weeks and must be at least five days on a stable dose of either paliperidone ER 6 mg or 9 mg or oral risperidone 4 mg or 6 mg once daily
  • Female patients of must have a negative human chorionic gonadotropin urine pregnancy test (ß-HCG) at visit 1 or must be for at least 1 year, surgically sterile, abstinent, or, if sexually active, agree to practice an effective method of before entry, throughout the study and at least one month after study end
  • Healthy control volunteers must be off all standard prescription drug therapy, over the counter compounds (OTC) and recreational substances/drugs for at least one week prior to participation in the study
  • Female volunteers of childbearing potential must have a negative ß -HCG pregnancy test at visit 1 or be postmenopausal for at least 1 year, surgically sterile, abstinent, or, if sexually active, agree to practice an effective method of birth control before entry, throughout the study and at least one month after the study end
  • Patients and volunteers must be able to read, understand and sign the Institutional Review Board approved form

Exclusion criteria

Exclusion Criteria:

  • Patients: Any depot neuroleptic medication (long acting injectables) in the last three months
  • Any antipsychotic compound, antidepressant, antiepileptic ("mood stabilizers"), lithium, anticholinergic within 2 weeks prior to study
  • Any psychopharmacologically active medication (except benzodiazepines, paracetamol and zopiclone as rescue medication) taken within the trial
  • Physical and psychological conditions that interfere with the study procedures, or could influence the study results, or could endanger the patient during the study
  • Alcohol and/or drug abuse four weeks prior to study start (patients with alcohol or drug abuse as defined by the criteria can participate if free of their of abuse for at least four weeks)
  • laboratory abnormality
  • Pregnant or breast feeding patients
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
2 participants (actual)

Study arms

  • Active comparator
    002

    Paliperidone ER 9 mg tablet once a day followed by PET scan in approximately 2 hours

    Drug: Paliperidone ER

  • Active comparator
    003

    Oral risperidone 4 mg tablet once a day followed by PET scan in approximately 2 hours

    Drug: Oral risperidone

  • Active comparator
    004

    Oral risperidone 6 mg tablet once a day followed by PET scan in approximately 2 hours

    Drug: Oral risperidone

  • Active comparator
    005

    Paliperidone ER 6 mg tablet once a day followed by PET scan in approximately 24 hours

    Drug: Paliperidone ER

  • Active comparator
    006

    Paliperidone ER 9 mg tablet once a day followed by PET scan in approximately 24 hours

    Drug: Paliperidone ER

  • Active comparator
    007

    Oral risperidone 4 mg tablet once a day followed by PET scan in approximately 24 hours

    Drug: Oral risperidone

  • Active comparator
    008

    Oral risperidone 6 mg tablet once a day followed by PET scan in approximately 24 hours

    Drug: Oral risperidone

  • Other
    009

    PET Scan PET Scan

    Other: PET Scan

  • Active comparator
    001

    Paliperidone ER 6 mg tablet once a day followed by PET scan in approximately 2 hours

    Drug: Paliperidone ER

Interventions

  • 9 mg tablet once a day followed by PET scan in approximately 2 hours

  • 6 mg tablet once a day followed by PET scan in approximately 2 hours

  • OtherPET Scan

    PET Scan

  • 4 mg tablet once a day followed by PET scan in approximately 24 hours

  • 4 mg tablet once a day followed by PET scan in approximately 2 hours

  • 6 mg tablet once a day followed by PET scan in approximately 2 hours

  • 6 mg tablet once a day followed by PET scan in approximately 24 hours

  • 6 mg tablet once a day followed by PET scan in approximately 24 hours

  • 9 mg tablet once a day followed by PET scan in approximately 24 hours

06

What researchers measure

Primary outcomes

  1. Percentage of Paliperidone or Risperidone Dopamine D2 Receptor Occupancies

    Time frame: Visit 3 (on day 3)

Secondary outcomes

  1. Plasma Concentrations of Paliperidone and Risperidone

    No measures available due to early termination of trial

    Time frame: Measurement of plasma concentration at Visit 3 (day 3)

  2. Assessment of the Ratio of Dopamine D2-receptor Occupancies in Two Different Areas of the Brain

    No measures available due to early termination of trial

    Time frame: Analysis of PET scans at Visit 3 (day 3)

07

Results

Posted Jan 11, 2011
Limitations and caveats
Two subjects enrolled, both completed study per protocol. Study was prematurely terminated, data obtained were not submitted to further statistical analysis and will not be applicable for scientific analysis due to the low number of subjects.

Participant flow

Participant flow — Overall Study
MilestonePaliperidone ER 6 mg Tablet Followed by PET Scan in 2 HoursPaliperidone ER 9 mg Tablet Followed by PET Scan in 2 HoursOral Risperidone 4 mg Tablet Followed by PET Scan in 2 HoursOral Risperidone 6 mg Tablet Followed by PET Scan in 2 HoursPaliperidone ER 6 mg Tablet Followed by PET Scan in 24 HoursPaliperidone ER 9 mg Tablet Followed by PET Scan in 24 HoursOral Risperidone 4 mg Tablet Followed by PET Scan in 24 HoursOral Risperidone 6 mg Tablet Followed by PET Scan in 24 HoursControl
Started010000001
Completed010000001
Not completed000000000

Outcome measures

PrimaryPercentage of Paliperidone or Risperidone Dopamine D2 Receptor Occupancies
Time frame:
Visit 3 (on day 3)
Reported as:
Number · percentage
Percentage of Paliperidone or Risperidone Dopamine D2 Receptor Occupancies
percentagePaliperidone ER 6 mg Tablet Followed by PET Scan in 2 HoursPaliperidone ER 9 mg Tablet Followed by PET Scan in 2 HoursOral Risperidone 4 mg Tablet Followed by PET Scan in 2 HoursOral Risperidone 6 mg Tablet Followed by PET Scan in 2 HoursPaliperidone ER 6 mg Tablet Followed by PET Scan in 24 HoursPaliperidone ER 9 mg Tablet Followed by PET Scan in 24 HoursOral Risperidone 4 mg Tablet Followed by PET Scan in 24 HoursOral Risperidone 6 mg Tablet Followed by PET Scan in 24 HoursControl
Percentage of Paliperidone or Risperidone Dopamine D2 Receptor Occupancies—0——————0
SecondaryPlasma Concentrations of Paliperidone and Risperidone

No measures available due to early termination of trial

Time frame:
Measurement of plasma concentration at Visit 3 (day 3)
Reported as:
Number

Results for this outcome have not been posted.

SecondaryAssessment of the Ratio of Dopamine D2-receptor Occupancies in Two Different Areas of the Brain

No measures available due to early termination of trial

Time frame:
Analysis of PET scans at Visit 3 (day 3)
Reported as:
Number

Results for this outcome have not been posted.

Adverse events

Non-serious events are listed at a 2% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Paliperidone ER 6 mg Tablet Followed by PET Scan in 2 Hours———
Paliperidone ER 9 mg Tablet Followed by PET Scan in 2 Hours—1/1 (100%)0/1 (0%)
Oral Risperidone 4 mg Tablet Followed by PET Scan in 2 Hours———
Oral Risperidone 6 mg Tablet Followed by PET Scan in 2 Hours———
Paliperidone ER 6 mg Tablet Followed by PET Scan in 24 Hours———
Paliperidone ER 9 mg Tablet Followed by PET Scan in 24 Hours———
Oral Risperidone 4 mg Tablet Followed by PET Scan in 24 Hours———
Oral Risperidone 6 mg Tablet Followed by PET Scan in 24 Hours———
Control—0/1 (0%)0/1 (0%)
Most frequent serious events
Most frequent serious events
EventPaliperidone ER 6 mg Tablet Followed by PET Scan in 2 HoursPaliperidone ER 9 mg Tablet Followed by PET Scan in 2 HoursOral Risperidone 4 mg Tablet Followed by PET Scan in 2 HoursOral Risperidone 6 mg Tablet Followed by PET Scan in 2 HoursPaliperidone ER 6 mg Tablet Followed by PET Scan in 24 HoursPaliperidone ER 9 mg Tablet Followed by PET Scan in 24 HoursOral Risperidone 4 mg Tablet Followed by PET Scan in 24 HoursOral Risperidone 6 mg Tablet Followed by PET Scan in 24 HoursControl
Exacerbation of schizophrenic symptomsPsychiatric disorders—1/1——————0/1

Baseline characteristics

Age, Categorical
Age, Categorical(participants)Paliperidone ER 6 mg Tablet Followed by PET Scan in 2 HoursPaliperidone ER 9 mg Tablet Followed by PET Scan in 2 HoursOral Risperidone 4 mg Tablet Followed by PET Scan in 2 HoursOral Risperidone 6 mg Tablet Followed by PET Scan in 2 HoursPaliperidone ER 6 mg Tablet Followed by PET Scan in 24 HoursPaliperidone ER 9 mg Tablet Followed by PET Scan in 24 HoursOral Risperidone 4 mg Tablet Followed by PET Scan in 24 HoursOral Risperidone 6 mg Tablet Followed by PET Scan in 24 HoursControlTotal
<=18 years—0——————00
Between 18 and 65 years—1——————12
>=65 years—0——————00
Age, Customized
Age, Customized(years)Paliperidone ER 6 mg Tablet Followed by PET Scan in 2 HoursPaliperidone ER 9 mg Tablet Followed by PET Scan in 2 HoursOral Risperidone 4 mg Tablet Followed by PET Scan in 2 HoursOral Risperidone 6 mg Tablet Followed by PET Scan in 2 HoursPaliperidone ER 6 mg Tablet Followed by PET Scan in 24 HoursPaliperidone ER 9 mg Tablet Followed by PET Scan in 24 HoursOral Risperidone 4 mg Tablet Followed by PET Scan in 24 HoursOral Risperidone 6 mg Tablet Followed by PET Scan in 24 HoursControlTotal
27 years of age—1 ± NA——————0 ± NA1
19 years of age—0——————11
Gender
Gender(participants)Paliperidone ER 6 mg Tablet Followed by PET Scan in 2 HoursPaliperidone ER 9 mg Tablet Followed by PET Scan in 2 HoursOral Risperidone 4 mg Tablet Followed by PET Scan in 2 HoursOral Risperidone 6 mg Tablet Followed by PET Scan in 2 HoursPaliperidone ER 6 mg Tablet Followed by PET Scan in 24 HoursPaliperidone ER 9 mg Tablet Followed by PET Scan in 24 HoursOral Risperidone 4 mg Tablet Followed by PET Scan in 24 HoursOral Risperidone 6 mg Tablet Followed by PET Scan in 24 HoursControlTotal
Female—0——————11
Male—1——————01
Region of Enrollment
Region of Enrollment(participants)Paliperidone ER 6 mg Tablet Followed by PET Scan in 2 HoursPaliperidone ER 9 mg Tablet Followed by PET Scan in 2 HoursOral Risperidone 4 mg Tablet Followed by PET Scan in 2 HoursOral Risperidone 6 mg Tablet Followed by PET Scan in 2 HoursPaliperidone ER 6 mg Tablet Followed by PET Scan in 24 HoursPaliperidone ER 9 mg Tablet Followed by PET Scan in 24 HoursOral Risperidone 4 mg Tablet Followed by PET Scan in 24 HoursOral Risperidone 6 mg Tablet Followed by PET Scan in 24 HoursControlTotal
Germany—1——————12
08

Study locations

1 site
  • Aachen, Germany
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Sep 2009, a primary completion of Dec 2009 and a completion of Dec 2009. It does not say whether these dates are actual or estimated.

Results were first posted in Jan 2011, 1 year 1 month after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 6, 2009
First posted
Jul 8, 2009
Start
Sep 2009
Primary completionActual
Dec 2009
CompletionActual
Dec 2009
Results first posted
Jan 11, 2011
Last update
Feb 11, 2014
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 11, 2014, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00934635
Responsible party
Sponsor
First posted
Jul 8, 2009
Start date
Sep 2009
Primary completion
Dec 2009
Completion
Dec 2009
Results posted
Jan 11, 2011
Last update
Feb 11, 2014

Study contacts

Janssen-Cilag G.m.b.H. Clinical Trial
study director · Janssen-Cilag G.m.b.H

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Jan 2014. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Paliperidone · Risperidone

Start the discussion